Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.
about
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicityDevelopment of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumventionEffect of dexrazoxane and amifostine on the vertebral bone quality of Doxorubicin treated male ratsAnthracyclines and the heart.Anthracyclines: cardiotoxicity and its prevention.Cardiotoxicity of cancer therapy.The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity.Early identification of anthracycline cardiomyopathy: possibilities and implications.Dexrazoxane as a cardioprotectant in children receiving anthracyclinesCardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric OncologDexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems databaseCardioprotective Effect of Grape Seed Extract on Chronic Doxorubicin-Induced Cardiac Toxicity in Wistar Rats.Preventing the cardiotoxicity of anthracyclines by dexrazoxane
P2860
Q28301317-695F10E9-6AE1-4EC1-8905-7E870A4E81B5Q28379015-C645AB92-9134-4D22-8EF4-FD8E87866856Q33455575-3B17C850-857E-4510-94D1-4AD345EE2574Q33613628-C406ACC2-E134-4329-9877-8836C609DD19Q33625243-55EDC087-92C4-4EA0-ACA3-9BAA75A4B65FQ33704056-2C59CE7A-4388-45DD-BCEE-8D60F232B468Q34120033-C669C8E5-A07E-4FA6-966E-231EF53941B7Q34800157-9F3CB3A4-CB9E-4875-A50D-8B95B21E3F3EQ35583768-3086FC43-6F61-4BA1-B84C-C104CA0CEBD2Q35849444-FA330015-808F-4DDC-9D6C-8A77D964923BQ36099606-605DB16C-BC95-41F5-BD68-0FEC554622BEQ36914391-DD8226FE-3AA2-4EB7-B557-134E3959ACD7Q37569911-ACF46A32-918F-4C52-9878-5354BB7E47F0Q39264529-F4374882-172B-4C82-AC24-E60745F9CE39Q42764756-FB802193-7BD5-4561-9549-375DB19F074B
P2860
Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.
description
1993 nî lūn-bûn
@nan
1993 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
name
Cardioprotection by ICRF187 ag ...... ildren with malignant disease.
@ast
Cardioprotection by ICRF187 ag ...... ildren with malignant disease.
@en
type
label
Cardioprotection by ICRF187 ag ...... ildren with malignant disease.
@ast
Cardioprotection by ICRF187 ag ...... ildren with malignant disease.
@en
prefLabel
Cardioprotection by ICRF187 ag ...... ildren with malignant disease.
@ast
Cardioprotection by ICRF187 ag ...... ildren with malignant disease.
@en
P2093
P2860
P356
P1476
Cardioprotection by ICRF187 ag ...... ildren with malignant disease.
@en
P2093
P2860
P304
P356
10.1136/HRT.70.2.185
P577
1993-08-01T00:00:00Z